Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
September 23, 2019 10:01 ET
|
Sermonix Pharmaceuticals LLC
COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...